5 Best Weight Loss Drug Stocks to Buy in 2026

Page 1 of 5

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. If you wish to see the full list, visit 5 Best Weight Loss Drug Stocks to Buy in 2026.

5. AstraZeneca PLC (NYSE:AZN)

Number of Hedge Fund Holders: 56

AstraZeneca PLC (NYSE:AZN) is one of the best weight loss drugs on this list.

TheFly reported on June 15 that AZN announced that its supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab) was accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application seeks approval for the treatment of adults with immunoglobulin A nephropathy (IgAN), a rare kidney disorder. The FDA’s Priority Review designation is given to therapies that have the potential to provide meaningful improvements in treatment options through benefits such as improved safety, effectiveness, or patient care. The FDA’s final decision on the application is expected in the fourth quarter of 2026.

This regulatory milestone closely follows another major commercial victory for the company’s oncology franchise. On June 12, AstraZeneca PLC (NYSE:AZN) announced that the U.S. Food and Drug Administration approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic prostate cancer. The approval applies to patients with metastatic androgen pathway modulation-naive or sensitive disease, identified through an FDA-authorized diagnostic test. The decision positions Truqap as a targeted treatment option for this specific patient population and expands AstraZeneca’s oncology portfolio with a new approach for managing advanced prostate cancer.

AstraZeneca PLC (NYSE:AZN) is a global biopharma company and is expanding into the obesity market with next-generation weight-loss therapies, including oral GLP-1 drugs and monthly injectables. The company aims to compete with market leaders while combining obesity treatments with its strong cardiovascular and metabolic disease portfolio.

Page 1 of 5
1281292 - 11759070 - 1